

1 **Full title:**

2 Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand:
3 Results from a Multicenter Observational Study

4

5 **Authors:**

6 Pinyo Rattanaumpawan¹; Supunee Jirajariyavej²; Kanokorn Lerdlamyong³; Nattawan
7 Palavutitotai⁴; Jatuporn Saiyarin⁵

8

9 **Affiliations:**

10 ¹Division of Infectious Diseases and Tropical Medicine, Department of Medicine,
11 Faculty of Medicine Siriraj Hospital, Bangkok, Thailand

12 ²Internal Medicine Unit, Taksin Hospital, Bangkok, Thailand

13 ³Internal Medicine Unit, Vachira Phuket Hospital, Phuket, Thailand

14 ⁴Internal Medicine Unit, Lerdsin Hospital, Bangkok, Thailand

15 ⁵Internal Medicine Unit, Central Hospital, Bangkok, Thailand

16

17 **Correspondence to:**

18 Pinyo Rattanaumpawan, MD, MSCE, PhD

19 2 Wanglang Road, Bangkoknoi,

20 Bangkok 10700, Thailand

21 Tel: (+66) 2-419-7784; Fax: (+66) 2-419-7783

22 E-mail: pinyo.rat@mahidol.ac.th

23

24 **Running title:** Favipiravir Therapy for COVID-19

25

26 **Keywords:** COVID-19, Favipiravir, Pneumonia

27

28 **Abstract word count:** 245

29

30 **Manuscript word count:** 2408

31

32 **Tables:** 3

33

34 **Figure:** 1

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **SYNOPSIS**

52 **Background.** Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity
53 against SARS-CoV-2. Presently, data on the effectiveness and optimal dosage of favipiravir
54 for treating COVID-19 is limited.

55 **Methods.** We conducted a retrospective observational study of hospitalized adult patients
56 with COVID-19 at five tertiary care hospitals in Thailand. We reviewed patient charts to
57 obtain all necessary data.

58 **Results.** Among 247 COVID-19 patients, 63 (23.0%) received ≥ 1 dose of favipiravir. Of
59 these, 27.0% required an O₂-nasal cannula, 9.5% required non-invasive ventilation and/or
60 high-flow O₂-therapy, and 6.4% required invasive mechanical ventilation and/or ECMO. The
61 median baseline NEWS2 score was 5(0–16). The Day-7 clinical improvement rate [95%CI]
62 was 66.7%[53.7–78.0%] in all patients, 92.5%[75.7%–99.1%] in patients who did not require
63 O₂-supplementation, and 47.2%[0.4%–64.5%] in patients who required O₂-supplementation.
64 No life-threatening adverse events were identified. The 28-day mortality rate was 4.8%.
65 Multivariate analysis revealed three poor prognostic factors for Day-7 clinical improvement
66 [odds ratio (95%CI); *p*-value]: older age [0.94 (0.89–0.99); *p*=0.04], higher baseline NEWS2
67 score [0.64 (0.47–0.88); *p*=0.006], and lower favipiravir loading dose (≤ 45 mg/kg/day) [0.04
68 (0.005–0.4); *p*=0.006].

69 **Conclusions.** Our study reports the promising effectiveness of favipiravir for treating
70 COVID-19 patients. In addition to older age and a high baseline NEWS2 score, a low loading
71 dose of favipiravir (≤ 45 mg/kg/day) was also identified as a poor prognostic factor for early
72 clinical improvement. Further studies to explore the optimal dose and the optimal timing of
73 drug initiation for favipiravir should be performed.

74

75

76 **INTRODUCTION**

77 As of 16-Jun-2020, a total of 7,941,791 COVID-19 cases with 434,796 deaths have been
78 reported globally.¹ This pandemic disease is caused by a novel coronavirus, named severe
79 acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a single-stranded
80 RNA beta-coronavirus encoding an RNA-dependent RNA polymerase (RdRp) and proteases.
81 Both RdRp and viral proteases are considered important targets for potentially therapeutic
82 agents. Hundreds of clinical studies are actively investigating a variety of promising agents
83 (e.g., remdesivir, favipiravir, lopinavir, hydroxychloroquine, and interferon-alpha)²; however,
84 data on the efficacy of these potentially therapeutic agents are still limited.

85 Favipiravir, a purine nucleic acid analog, is a broad-spectrum oral antiviral agent that
86 inhibits the *RdRp* of RNA viruses.³ This agent shows in vitro activity against many RNA
87 viruses, including arenaviruses, bunyaviruses, flaviviruses, Ebola virus, and influenza virus,
88 as well as SARS-CoV-2.^{4,5} Currently, two registered clinical studies of favipiravir among
89 COVID-19 patients have already reported their results.⁶ The first study
90 (ChiCTR2000029600) was a small, open-label, nonrandomized control study of 80 patients
91 with COVID-19 conducted to compare the efficacy of favipiravir plus aerosolized interferon-
92 alpha with that of lopinavir/ritonavir plus aerosolized interferon-alpha. In that study, the
93 favipiravir group showed a significantly shorter time to viral clearance and a significantly
94 higher improvement rate in chest imaging, after adjustment for potential confounders.⁷ The
95 second study (ChiCTR200030254) was a randomized control trial (RCT) of 240 patients with
96 COVID-19 pneumonia. That study, currently available as a preprint on MedRxIV, reported a
97 significantly higher clinical recovery rate on Day 7 in the favipiravir group compared with
98 the arbidol group (71.43% vs. 55.86%; $p = 0.02$).⁸

99 In February 2020, favipiravir was made available for use in Thailand under
100 emergency procurement by the Department of Disease Control of Thailand. In early March

101 2020, Thailand national clinical practice guidelines (CPG) for COVID-19 management
102 recommended the initiation of favipiravir therapy in only patients with severe COVID-19
103 pneumonia (pneumonia with required high-flow O₂-supplementation, non-invasive
104 mechanical ventilation, or invasive mechanical ventilation to maintain a patient O₂-saturation
105 of 90% or more). In early May 2020, the national CPG were revised, and favipiravir is now
106 also recommended for the treatment of mild pneumonia (i.e., abnormal chest-x-ray without
107 desaturation). The benefits of early favipiravir initiation in mild COVID-19 cases are in need
108 of further investigation.

109 The standard dose of favipiravir for treating influenza infection is 1600 mg twice
110 daily on Day 1, followed by 600 mg twice daily on Days 2–5.⁹ A maximal loading dose of
111 3000 mg twice daily on Day 1 and a maintenance dose of 1200 mg twice daily on Days 2–9
112 were safely used in a previous Ebola study.¹⁰ Given that the optimal dose of favipiravir for
113 treating COVID-19 is still uncertain, the Thailand national CPG recommend a fixed loading
114 dose of 1600 mg twice daily on Day 1, followed by 600 mg twice daily on Days 2–10. A
115 higher loading dose (60 mg/kg/day, MKD) and maintenance dose (20 MKD) are
116 recommended in patients with a body mass index (BMI) of ≥ 35 .

117 Presently, data on the effectiveness and optimal dosage of favipiravir for treating
118 COVID-19 is limited. Therefore, we conducted a retrospective study to explore these issues.

119

120 **MATERIALS AND METHODS**

121 **Study Design**

122 We conducted a retrospective observational study of COVID-19 patients who were
123 hospitalized at any of five tertiary care hospitals in Thailand (i.e., Siriraj, Taksin, Vachira
124 Phuket, Lerdsin, and Central hospitals) during 1 January – 30 April 2020. The study protocol

125 was approved with a waiver of informed consent by the institutional review boards of all
126 involved hospitals.

127 **Inclusion and Exclusion Criteria**

128 We enrolled all hospitalized patients aged at least 18 years who had reverse transcription
129 PCR-confirmed SARS-CoV-2 based on a respiratory specimen (nasopharyngeal,
130 oropharyngeal, sputum, endotracheal aspirate, or bronchoalveolar lavage sample) and
131 received at least one dose of favipiravir. Patients who expired or were discharged from the
132 hospital within 24 hours after hospitalization were excluded.

133 **Data Collection and Study Definition**

134 We reviewed patient charts to obtain all necessary data, including demographic data, clinical
135 data, laboratory data, and the hospital stay length. We also recorded the daily National Early
136 Warning Score 2 (NEWS2 score). Details regarding the NEWS2 score have been published
137 elsewhere.¹¹ The primary outcome was the rate of clinical improvement within seven days of
138 favipiravir therapy (Day-7 clinical improvement), and the secondary outcomes were the Day-
139 14 and Day-28 clinical improvement rates.

140 Clinical improvement was defined as a one-point reduction in baseline status (on the
141 first day of favipiravir therapy) on a six-point disease severity scale at the time of evaluation.
142 The six-point disease severity scale was categorized as follows: 6-death; 5-hospitalization for
143 extracorporeal membrane oxygenation (ECMO) or mechanical ventilation; 4-hospitalization
144 for non-invasive ventilation or high-flow O₂-therapy; 3-hospitalization for supplemental O₂;
145 2-hospitalization without the need for O₂-supplementation but requiring ongoing medical
146 care; and 1-discharge or normalization of all vital signs and saturation of peripheral O₂ of
147 >94% on room air for at least 24 hours.

148

149

150 **Statistical Analysis**

151 Categorical variables are summarized by frequency and percentage, whereas
152 continuous variables are summarized by the median and range. Univariate analyses were
153 performed using the Fisher-exact test for categorical data. The Mann-Whitney U test was
154 used for continuous data. To identify the factors independently associated with the Day-7
155 clinical improvement, we performed a subsequent multivariate analysis including all
156 potentially significant variables with a p -value of ≤ 0.20 in a stepwise fashion.

157 For all calculations, a two-tailed p -value of < 0.05 was considered statistically
158 significant. All calculations were performed using STATA version 14.1 (Stata Corp, College
159 Station TX).

160

161 **RESULTS**

162 During the study period, there were a total of 274 COVID-19 patients hospitalized in the
163 participating hospitals, of which 63 patients (23.0%) received favipiravir. The baseline
164 demographics and characteristics of all patients are listed in Table 1.

165 The median age of favipiravir-treated COVID-19 patients was 48 (22–85) years, and
166 39 of these patients (61.9%) were male. Most patients had fever (87.3%), sore throat (69.8%),
167 or cough (74.6%) as the clinical presentation. The median duration between the symptom
168 onset and the admission date was 6 (0–28) days, while the median duration between the
169 symptom onset and the first day of favipiravir therapy was 8 (0–28) days.

170 At baseline (Day 1 of favipiravir therapy), 17 patients (27.0%) required O₂-
171 supplementation via nasal cannula, 6 patients (9.5%) required non-invasive ventilation and/or
172 high-flow O₂-therapy, and 4 patients (6.4%) required invasive mechanical ventilation and/or
173 ECMO, while the remainder did not required O₂-supplementation. The median baseline
174 NEWS2 score was 5 (0–16).

175 The median loading dose of favipiravir was 47.4 (29.1–71.1) MKD, and one-third of
176 enrolled patients (33.3%) received a loading dose of ≤ 45 MKD. The median maintenance
177 dose of favipiravir was 17.9 (10.9–26.7) MKD, and 76.2% of the subjects received a
178 maintenance dose of ≤ 15 MKD. The median duration of favipiravir therapy was 12 (2–17)
179 days. Within two days of initiating favipiravir treatment, nearly all patients were prescribed a
180 chloroquine-based agent (98.4%) and a protease inhibitor (96.8%); half of them also received
181 azithromycin (49.2%). Only a few patients received a steroid (12.7%) or tocilizumab (6.4%)
182 at this time.

183 **Hospital Course and Treatment Outcomes**

184 Details regarding the hospital course and treatment outcomes are shown in Table 2. The Day-
185 7, Day-14, and Day-28 clinical improvement rates, stratified by the requirement for O₂-
186 supplementation are depicted in Figure 1. The Day-7 clinical improvement rate [95% CI] was
187 66.7% [53.7–78.0%] in all patients, 92.5% [75.7–99.1%] in patients who did not require O₂-
188 supplementation (a six-point disease severity scale score of 1–2), and 47.2% [0.4–64.5%] in
189 patients who required O₂-supplementation (a six-point severity scale score of 3–5). The Day-
190 14 clinical improvement rates for all patients, those who did not require O₂-supplementation,
191 and those who required O₂-supplementation were 85.7% [74.6%–93.2%], 100.0% [87.2%–
192 1.00%], and 75.0% [57.8%–87.9%], respectively. Nearly all patients who required O₂-
193 supplementation (96.1%) had clinical improvement within 28 days.

194 Of the 63 favipiravir-treated patients, four patients required invasive mechanical
195 ventilation or ECMO on Day 1 of therapy, and four more cases subsequently required
196 invasive mechanical ventilation (two cases on Day 6 and two cases on Day 9 of therapy). The
197 14-day, 28-day, and in-hospital mortality rates were 1.6%, 4.8%, and 7.9%, respectively. The
198 major cause of death was superimposed infection.

199 The most common adverse event was diarrhea (54.0%), follow by nausea/vomit
200 (7.9%), hepatitis (6.4%), and QT interval prolongation in EKG (6.4%). None of these adverse
201 events were life-threatening.

202 **Factors Associated with Day-7 Clinical Improvement**

203 To determine the factors associated with Day-7 clinical improvement, we compared patients
204 with Day-7 clinical improvement (cases) with patients without Day-7 clinical improvement
205 (controls). The characteristics of both groups are shown Table 1. The cases had a
206 significantly lower age (47 vs. 59 years; $p = 0.02$), a significantly lower BMI (25.0 vs. 27.9; p
207 = 0.04), a significantly lower baseline NEWS2 score (4 vs. 5; $p = 0.003$), and a significantly
208 lower baseline six-point disease severity scale score (2 vs. 3; $p < 0.001$). Additionally, the
209 baseline white blood cell count was significantly lower in the case group (5420 vs. 6810; $p =$
210 0.03). Although the median loading and maintenance doses of favipiravir were not
211 statistically different between these groups, the proportion of patients in the control group
212 who received a lower loading dose of favipiravir (≤ 45 MKD) trended higher compared with
213 the case group (26.2% vs. 47.6%; $p < 0.10$).

214 Table 3 shows the results of multivariate analysis. A multivariate analysis revealed three
215 factors that were negatively associated with Day-7 clinical improvement [odds ratio (95%CI);
216 p -value]: older age [0.94 (0.89–0.99); $p = 0.04$], higher baseline NEWS2 score [0.64 (0.47–
217 0.88); $p = 0.006$], and a lower prescribed loading dose of favipiravir (≤ 45 MKD) [0.04
218 (0.005–0.4); $p = 0.006$].

219

220 **DISCUSSION**

221 The Day-7 clinical improvement rate from our study was 67.7%, which is slightly lower than
222 the Day-7 clinical recovery rate from the abovementioned RCT of favipiravir (71.4%).⁸

223 However, there were a few differences between these two studies. First, the definition of

224 clinical recovery used in the abovementioned RCT was based mainly on clinical symptoms
225 (e.g., fever, cough), whereas the definition of clinical improvement used in our study was
226 based on improvement in oxygenation status. Our study included sicker patients with a higher
227 proportion of patients who required mechanical ventilation (6.4%) as compared with the
228 subjects of the unpublished RCT (0.9%). These differences may explain the slightly lower
229 rate of favorable clinical responses observed in the present study.

230 Among the COVID-19 patients who did not require O₂-supplementation, nearly all
231 patients (92.6%) had clinical improvement within the first seven days of favipiravir therapy.
232 However, only half of the patients who required O₂-supplementation (47.2%) had clinical
233 improvement within the first seven days of therapy. The rate of clinical improvement in these
234 patients finally reached 75% on Day 14 and 83.3% on Day 28. Of the eight patients who
235 required invasive mechanical ventilation or ECMO during their hospitalization, one patient
236 died within the first 14 days. Therefore, the calculated 14-day mortality among this group
237 was 12.5%. This number is similar to the 14-day mortality reported by a preliminary
238 remdesivir RCT, in which 13 (10.4%) out of 125 patients who required mechanical
239 ventilation or ECMO died.¹² Based on these findings, the effectiveness of favipiravir for
240 treating COVID-19 is promising, but this drug can be slow acting in more severe cases.

241 Our study identified older age and a higher baseline NEWS2 scale as poor prognostic
242 factors for early clinical response. These findings are compatible with the results from many
243 previous publications.¹³⁻¹⁵ We also explored other baseline variables (e.g., BMI,
244 comorbidities); however the impact of those factors disappeared after the data were adjusted
245 by the baseline NEWS2 scale.

246 Given that the optimal dose of favipiravir is still uncertain, we carefully explored the
247 association between favipiravir dosage and patient outcome. Our study confirmed that a
248 loading dose of favipiravir of ≤ 45 MKD was a poor prognostic factor for early clinical

249 response. Therefore, a fixed favipiravir loading dose of 1600 mg twice daily for all patients
250 with a BMI of <35 may be suboptimal for patients with a BMI of <35 but a body weight of
251 ≥ 70 kg. Some might argue that this significant association may be a reflection of patients'
252 obesity, which was also known as a poor prognostic factor in COVID-19. However, our study
253 did not find any association between the patient's baseline BMI or body weight and the
254 treatment outcome in the multivariate analysis.

255 Our study has several strengths. First, this study was a very early study to explore the
256 effectiveness of favipiravir in active clinical cases of COVID-19. Second, this study included
257 patients with differing disease severities; the patients ranged from mild pneumonia cases who
258 did not require O₂-supplementation to patients with life-threatening pneumonia who required
259 mechanical ventilation or ECMO. This diverse subject pool allowed us to thoroughly explore
260 the effectiveness of favipiravir and the clinical course of COVID-19 disease in various
261 degrees of severity. Lastly, the daily NEWS2 scores and six-point disease severity scale
262 scores were carefully collected and analyzed. Consequently, we can report nearly all
263 important clinical outcomes and compare our findings with those of other clinical trials.^{7, 8, 12}

264 Our study also has some limitations. First, the retrospective design resulted in a
265 significant amount of missing data, especially for laboratory values. To resolve this issue,
266 when performing the multivariate analysis, missing data was replaced by the mean value of a
267 given variable. Second, majority of our patients also received chloroquine-based agent and
268 protease inhibitors. Therefore, the good treatment response among our patients may be the
269 synergistic results of triple combination of favipiravir, chloroquine-based agent and protease
270 inhibitors. Furthermore, a high rate (54.0%) of diarrhea of the patients having favipiravir was
271 probably related to protease inhibitor rather than favipiravir. Third, a sample size of 63
272 patients with COVID-19 pneumonia is not large enough to detect other associated factors
273 with a low prevalence. Lastly, the generalizability of our findings may be an issue. Given that

274 the study was conducted in tertiary care hospitals in Thailand, results may not be applicable
275 to primary or secondary care settings or to COVID-19 patients in other countries.

276 In conclusion, our study reports the promising effectiveness of favipiravir for treating
277 COVID-19 patients in a tertiary care hospital setting. No life-threatening adverse events were
278 identified. In addition to older age and a high baseline NEWS2 score, a low loading dose of
279 favipiravir (≤ 45 MKD) was also identified as a poor prognostic factor for early clinical
280 improvement. Further studies to explore the optimal dose and the optimal timing of drug
281 initiation for favipiravir should be performed.

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299 **Notes.**

300 **Acknowledgments.** The authors gratefully acknowledge the study team at all involved
301 hospitals for their assistance of this study. Siriraj hospital: Mrs. Surangkana Samanloh;
302 Taksin hospital: Mrs. Duangruethai Jankiew, Dr. Kittipong Sae-lao and Ms. Potjana Chularat;
303 Vachira Phuket hospital: Ms. Somruedee Chatchawej and Dr. Busaya Santisant; Lerdsin
304 hospital: Ms. Pranee Watagulsin; Central hospital: Ms. Nattasin Pimhom and Ms. Pornsikan
305 Charutchocksawat. Additionally, we thank Katie Oakley, PhD, from Edanz Group ([https://en-](https://en-author-services.edanzgroup.com/)
306 [author-services.edanzgroup.com/](https://en-author-services.edanzgroup.com/)) for editing a draft of this manuscript.

307

308 **Financial support.** This research project was supported by Siriraj Research Fund, Grant
309 number (IO) R016333038, Faculty of Medicine Siriraj Hospital, Mahidol University.

310

311 **Potential conflicts of interest.** The authors have no conflicts of interest to declare.

312

313 **Authors' contributions.** All authors made substantial contribution to the interpretation and
314 analysis of data. The corresponding author had full access to the data and responsibility for
315 the decision to submit the manuscript for publication.

316

317

318

319

320

321

322

323

324

325 **References**

- 326 1. World Health Organization. Coronavirus disease (COVID-19) Situation Report – 139.
327 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139.pdf?sfvrsn=79dc6d08_2)
328 [139.pdf?sfvrsn=79dc6d08_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139.pdf?sfvrsn=79dc6d08_2) (accessed June 8, 2020).
- 329 2. Srinivas P, Sacha G, Koval C. Antivirals for COVID-19. *Cleve Clin J Med* 2020.
- 330 3. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral
331 RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci* 2017; **93**: 449-63.
- 332 4. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against
333 influenza virus. *Antimicrob Agents Chemother* 2005; **49**: 981-6.
- 334 5. Bai CQ, Mu JS, Kargbo D et al. Clinical and Virological Characteristics of Ebola Virus
335 Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. *Clin Infect Dis* 2016; **63**:
336 1288-94.
- 337 6. Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for
338 2019-nCoV Infection. *Clin Pharmacol Ther* 2020.
- 339 7. Cai Q, Yang M, Liu D et al. Experimental Treatment with Favipiravir for COVID-19: An
340 Open-Label Control Study. *Engineering (Beijing)* 2020.
- 341 8. Chang Chen, Jianying Huang, Zhenshun Cheng et al. Favipiravir versus Arbidol for COVID-
342 19: A Randomized Clinical Trial. *medRxiv preprint* <https://doi.org/10.1101/2020031720037432> [e-pub
343 ahead of print] 2020.
- 344 9. Wang Y, Fan G, Salam A et al. Comparative Effectiveness of Combined Favipiravir and
345 Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus
346 Infection. *J Infect Dis* 2020; **221**: 1688-98.
- 347 10. Nguyen TH, Guedj J, Anglaret X et al. Favipiravir pharmacokinetics in Ebola-Infected
348 patients of the JIKI trial reveals concentrations lower than targeted. *PLoS Negl Trop Dis* 2017; **11**:
349 e0005389.
- 350 11. Royal College of Physicians National Early Warning Score (NEWS) 2: Standardising the
351 assessment of acute-illness severity in the NHS. Updated report of a working party London: RCP,
352 2017.

- 353 12. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 -
354 Preliminary Report. *N Engl J Med* 2020.
- 355 13. Goyal P, Choi JJ, Pinheiro LC et al. Clinical Characteristics of Covid-19 in New York City. *N*
356 *Engl J Med* 2020; **382**: 2372-4.
- 357 14. Grasselli G, Zangrillo A, Zanella A et al. Baseline Characteristics and Outcomes of 1591
358 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020.
- 359 15. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel
360 coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506.

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383 **Table 1.** Baseline demographics and characteristics of all patients.

Variables	All (n = 63)	Day 7 Clinical improvement		p-value
		Yes (n = 42)	No (n = 21)	
Age, median (range), year	48 (22–85)	47 (23–72)	59 (22–85)	0.02
Male sex	39 (61.9%)	25 (59.5%)	14 (66.7%)	0.78
Body weight, median (range), kg	69 (45–125)	68 (51–125)	76 (45–120)	0.08
Body mass index median (range), kg/m ²	26.1 (19.0–43.8)	25.0 (19.0–43.8)	27.9 (20.8–39.2)	0.04
Duration between, median (range), day				
Symptom onset and admission date	6 (0–28)	6 (0–28)	8 (0–15)	0.08
Admission date and Day-1 of favipiravir therapy	1 (-8–10)	1 (-3–10)	0 (-8–5)	0.002
Symptom onset and Day-1 of favipiravir therapy	8 (0–28)	8 (2–28)	8 (0–11)	0.60
Exposure risk				
Contact with confirmed COVID-19 cases	26 (41.3%)	19 (45.2%)	7 (33.3%)	0.42
Travel abroad	7 (11.1%)	5 (11.2%)	2 (9.5%)	1.00
Contact with a foreigner	11 (17.5%)	8 (19.1%)	3 (14.3%)	0.74
Travel to a local area with clustered cases	38 (60.3%)	28 (66.7%)	10 (47.6%)	0.18
Underlying diseases				
Heart disease and hypertension	9 (14.3%)	7 (16.7%)	2 (9.5%)	0.71
Diabetes mellitus	17 (27.0%)	11 (26.2%)	6 (28.6%)	1.00
Chronic lung disease	4 (6.4%)	2 (7.1%)	1 (4.8%)	1.00
Chronic kidney disease	4 (6.4%)	3 (7.1%)	1 (4.8%)	1.00
Chronic liver disease	3 (4.8%)	3 (7.1%)	0 (0%)	0.55
Solid cancer	4 (6.4%)	2 (7.1%)	1 (4.8%)	1.00
Others	4 (6.4%)	2 (7.1%)	2 (9.5%)	0.60
Clinical presentation upon admission				
Fever or body temperature of >37.5 °C	55 (87.3%)	36 (85.7%)	19 (90.5%)	0.71

Sore throat	44 (69.8%)	27 (64.3%)	17 (81.0%)	0.25
Rhinorrhea	16 (25.4%)	13 (31.0%)	3 (14.3%)	0.22
Cough	47 (74.6%)	30 (71.4%)	17 (81.0%)	0.54
Headache	11 (17.5%)	8 (19.1%)	3 (14.3%)	0.74
Myalgia	17 (27.0%)	12 (28.6%)	5 (23.8%)	0.77
Diarrhea	8 (12.7%)	6 (14.3%)	2 (9.5%)	0.71
Shortness of breath	27 (42.9%)	14 (33.3%)	13 (61.9%)	0.06
Illness severity at the time of favipiravir initiation				
NEWS2 score, median (range)	5 (0–16)	4 (0–11)	5 (0–16)	0.003
Six-point disease severity scale, median (range)	2.5 (1–5)	2 (1–4)	3 (2–5)	<0.001
1 – No O ₂ -supplementation with O ₂ -saturation of >94%	4 (6.4%)	4 (6.4%)	0 (0)	<0.001
2 – No O ₂ -supplementation with O ₂ -saturation of ≤94%	23 (36.4%)	21 (50.0%)	2 (9.5%)	
3 –Requiring O ₂ -supplementation	28 (44.4%)	16 (40.1%)	12 (57.1%)	
4 –Requiring high-flow O ₂ -supplementation or non-invasive mechanical ventilation	4 (6.4%)	1 (2.4%)	3 (14.3%)	
5 –Requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation	4 (6.4%)	0 (0%)	4 (19.1%)	
Baseline laboratory values*				
Hemoglobin, median (range), (mg/dl)	14.0 (8.0–18.0)	14.0 (9.0–17.0)	13.5 (8.0–18.0)	0.48
White blood cell count, median (range), (cell/mm ³)	5735 (2910–41300)	5420 (2910–41300)	6810 (3180–15750)	0.03
Serum creatinine, median (range), (mg/dl)	0.9 (0.3–22.9) (n = 58)	0.9 (0.4–22.9) (n = 27)	0.9 (0.33–5.1) (n = 21)	0.67
Serum albumin, median (range), (mg/dl)	4.0 (1.8–4.9) (n = 53)	4.2 (1.8–5.0) (n = 33)	3.5 (2.6–4.1) (n = 20)	0.002
Serum lactate dehydrogenase, median (range), (mg/dl)	404 (145–1094) (n = 30)	382 (145–567) (n = 17)	453 (313–1094) (n = 13)	0.03

Indication of favipiravir therapy				
Abnormal chest imagining only	26 (41.3%)	24 (57.1%)	2 (9.5%)	<0.001
Required O ₂ -supplementation only	3 (4.7%)	2 (4.7%)	1 (4.8%)	
Abnormal chest imaging and required O ₂ -supplementation	34 (54.0%)	16 (38.1%)	18 (85.7%)	
Favipiravir regimen				
Dose per bw, median (range), mg/kg/day				
Loading dose	47.4 (29.1–71.1)	49.2 (29.1–62.7)	45.7 (29.6–71.1)	0.47
Maintenance dose	17.9 (10.9–26.7)	18.5 (10.9–23.5)	17.1 (11.1–26.7)	0.37
Potentially sub-therapeutic dose				
Loading dose of ≤45 MKD	21 (33.3%)	11 (26.2%)	10 (47.6%)	0.10
Maintenance dose of ≤15 MKD	48 (76.2%)	33 (78.6%)	15 (71.4%)	0.55
Duration of therapy, median (range), day	12 (2–17)	11.5 (2–16)	12 (2–17)	0.02
Other medications used**				
Any chloroquine-based agent	62 (98.4%)	41 (97.6%)	21 (100%)	1.00
Hydroxychloroquine	54 (85.7%)	36 (85.7%)	18 (85.7%)	1.00
Chloroquine	14 (22.2%)	8 (19.1%)	6 (28.6%)	0.52
Any protease inhibitor	61 (96.8%)	40 (95.2%)	21 (100,0%)	0.55
Darunavir/ritonavir	51 (81.0%)	35 (83.3%)	16 (76.2%)	0.51
Lopinavir/ritonavir	22 (34.9%)	13 (31.0%)	9 (42.9%)	0.26
Azithromycin	31 (49.2%)	17 (40.5%)	14 (66.7%)	0.06
Steroid	8 (12.7%)	5 (11.9%)	3 (14.3%)	1.00
Tocilizumab	4 (6.4%)	1 (2.4%)	3 (14.3%)	0.10

384 **Note.** *Earliest results of a test obtained within the first 7 days of admission (missing data was
385 replaced by the mean value of the variable)

386 ** Medications used within 2 days before or after the initiation of favipiravir therapy

387

388

389

390 **Table 2.** Hospital course and treatment outcomes

Variables	All patients (n = 63)
Clinical improvement	
Day-7 clinical improvement	42 (66.7%)
Patients who did not require O ₂ -supplementation (n = 27)	25 (92.6%)
Patients who required O ₂ -supplementation (n = 36)	17 (47.2%)
Day-14 clinical improvement	54 (85.7%)
Patients who did not require O ₂ -supplementation (n = 27)	27 (100.0%)
Patients who required O ₂ -supplementation (n = 36)	27 (75.0%)
Day-28 clinical improvement	57 (90.5%)
Patients who did not require O ₂ -supplementation (n = 27)	27 (100.0%)
Patients who required O ₂ -supplementation (n = 36)	30 (83.3%)
ICU duration, median (range), day	0 (0–46)
Required invasive mechanical ventilation or ECMO* during hospitalization	8 (12.7%)
Before initiation of favipiravir	4 (6.3%)
After initiation of favipiravir	4 (6.3%)
14-day mortality rate	1 (1.6%)
28-day mortality rate	3 (4.8%)
In-hospital mortality rate	5 (7.9%)
Length of hospital stay, median (range), day	15 (2–47)
Adverse drug reactions	39 (61.9%)
Diarrhea	34 (54.0%)
Hepatitis	4 (6.4%)
QT interval prolongation	4 (6.4%)
Nausea and vomit	5 (7.9%)
Superimposed bacterial infection	8 (12.7%)

391 **Note.** *ECMO: extracorporeal membrane oxygenation

392 **Table 3.** Factors associated with Day-7 clinical improvement

Variables	Unadjusted Odd Ratio [95%CI ; <i>p</i> -value]	Adjusted Odd Ratio [95%CI ; <i>p</i> -value]
Age, year	0.95 [0.92 -0.99; <i>p</i> =0.02]	0.94 [0.89–0.99; <i>p</i> =0.04]
Baseline NEWS2 score	0.77 [0.65-0.92; <i>p</i> =0.004]	0.64 [0.47 – 0.88; <i>p</i> =0.006]
Low loading dose of favipiravir	0.39 [0.13-1.17; <i>p</i> =0.09]	0.04 [0.005–0.41; <i>p</i> =0.006]

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409


410

411

412

413

414 **Figure 1.** Rate of clinical improvement on Day 7, Day 14, and Day 28 of favipiravir therapy,
415 stratified by the requirement for O₂-supplementation.



416